Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autoimmune disease characterized by blisters on the skin.
Biomarker and diagnostic research for autoimmune bullous skin disease has been reported in the published literature.
3 clinical trials registered, 3 recruiting. Interventions under study include other interventions and biologic therapy. Research is primarily sponsored by academic and government institutions.
101 publications have been identified in PubMed for autoimmune bullous skin disease. Research spans Case Report / Case Series (62%), Review / Meta-Analysis (15%), and Basic Science / Preclinical (7%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 63 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 11:57 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries | 15 | 15% |
Laboratory research | 7 | 7% |
Disease patterns and progression | 6 | 6% |
Testing and diagnosis research | 4 | 4% |
Other research | 3 | 3% |
New treatment approaches | 2 | 2% |
Clinical study results | 1 | 1% |
Carlson K (2026). [PMID: 29261895](https://pubmed.ncbi.nlm.nih.gov/29261895/). *Unknown Journal*. [Case Report / Case Series]
Avcı C (2026). [PMID: 41923357](https://pubmed.ncbi.nlm.nih.gov/41923357/). *J Cutan Pathol*. [Case Report / Case Series]
Ancker G (2026). [PMID: 41563431](https://pubmed.ncbi.nlm.nih.gov/41563431/). *Dermatologie (Heidelberg, Germany)*. [Case Report / Case Series]
Bernett CN (2026). [PMID: 30252369](https://pubmed.ncbi.nlm.nih.gov/30252369/). *Unknown Journal*. [Case Report / Case Series]
Ghane Y (2026). [PMID: 41396376](https://pubmed.ncbi.nlm.nih.gov/41396376/). *Inflammopharmacology*. [Review / Meta-Analysis]
Kang RS (2026). [PMID: 41616933](https://pubmed.ncbi.nlm.nih.gov/41616933/). *Journal of the American Academy of Dermatology*. [Case Report / Case Series]
Zulaika-Lloret M (2026). [PMID: 41980060](https://pubmed.ncbi.nlm.nih.gov/41980060/). *Australas J Dermatol*. [Other]
Sathe NC (2026). [PMID: 32119399](https://pubmed.ncbi.nlm.nih.gov/32119399/). *Unknown Journal*. [Case Report / Case Series]
Ali I (2026). [PMID: 41378313](https://pubmed.ncbi.nlm.nih.gov/41378313/). *JAAD case reports*. [Review / Meta-Analysis]
Yadav R (2026). [PMID: 41473884](https://pubmed.ncbi.nlm.nih.gov/41473884/). *Clinical case reports*. [Case Report / Case Series]
AI-curated news mentioning autoimmune bullous skin disease
Updated Aug 13, 2026
Recent research highlights advancements in biologic therapies for autoimmune skin diseases, showcasing their potential to transform treatment approaches. The study emphasizes the evolving landscape of therapeutic options aimed at improving patient outcomes.
A recent study explores the correlation between platelet-related parameters and autoantibodies in patients with autoimmune bullous diseases. This research could provide insights into the pathophysiology of these conditions and inform future therapeutic strategies.